AstraZeneca’s Dapagliflozin gets marketing authorisation for chronic kidney disease in India
AstraZeneca India has received marketing authorisation for their anti-diabetic drug dapagliflozin, in India for the treatment of…
Recover your password.
A password will be e-mailed to you.
- Advertisement -
Recover your password.
A password will be e-mailed to you.